GENOME-WIDE SCREENING FOR SNPs AND MUTATIONS RELATED TO DISEASE CONDITIONS

• US 20110082047A1
• Filed: 07/30/2007
• Published: 04/07/2011
• Est. Priority Date: 07/31/2006
• Status: Abandoned Application

• Current Assignee: Deutsches Krebsforschungszentrum
• Original Assignee: Deutsches Krebsforschungszentrum
• Inventors: Hoheisel, Jörg, Angenendt, Philipp
• Application Number:
  US12/309,765
• Publication Number:
  US 20110082047A1
• Time in Patent Office: Days
• US Class Current: 506/9
• CPC Class Codes: C12Q 1/6809 Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2521/313 Type II endonucleases, i.e. cutting outside recognition site
• CPC Class Codes: C12Q 2537/113 Heteroduplex formation
• CPC Class Codes: C12Q 2539/101 Subtraction analysis

Abstract

The present invention provides a genome-wide methodology for identifying single nucleotide polymorphisms and mutations related to disease conditions, such as cancer. Specifically, the invention provides methods for detecting genome-wide mutations by successively amplifying sequence differences between two sample populations.

Claims

1. A method for identifying a genome-wide mutation, comprising:

(a) providing DNA from two sample pools of a subject, wherein a first sample pool is obtained from an diseased cell and a second sample pool is obtained from a normal cell;

(b) digesting each DNA sample pool to generate at least two DNA fragments;

(c) ligating a short oligonucleotide adapter to each fragment at a site of mismatch cleavage; and

(d) selectively amplifying and identifying the sequence differences between the two sample pools to identify a mutation.

2. The method of claim 1, wherein the diseased cell is a cancer cell.

3. The method of claim 1, wherein the selectively amplifying and identifying means are selected from the group consisting of differential display, representational differential analysis, suppressive subtraction hybridization, serial analysis of gene expression, gene expression microarray, nucleic acid chip technology, and direct sequencing.

4. The method of claim 3, wherein the selectively amplifying and identifying means is suppressive subtraction hybridization.

5. The method of claim 1, wherein the individual is a mammal, plant, fungus, reptile, bird, fish, insect, bacterium, or virus.

6. The method of claim 5, wherein the mammal is selected from the group consisting of a human, dog, cat, cattle, pig, sheep, rat, mouse, guinea pig, hamster, horse, cow, chicken, and rodent.

7. The method of claim 6, wherein the mammal is a human.

8. A method for identifying a oncogenic mutation comprising:

(a) providing DNA from two sample pools of a subject, wherein a first sample pool is obtained from a cancer cell and a second sample pool is obtained from a normal cell;

(b) digesting each DNA sample pool to generate DNA fragments;

(c) ligating a short oligonucleotide adapter to each fragment at a site of mismatch cleavage; and

(d) selectively amplifying and identifying the sequence differences between the two sample pools to identify an oncogenic mutation.

9. A method for identifying a genome-wide mutation, comprising:

(a) providing DNA from two sample pools of a subject, wherein a first sample pool is obtained from an diseased cell and a second sample pool is obtained from a normal cell;

(b) digesting each DNA sample pool to generate at least two DNA fragments;

(c) ligating a short oligonucleotide adapter carrying a recognition site for a type IIS restriction endonuclease to each fragment at a site of mismatch cleavage;

(d) digesting all fragments with a type IIS restriction endonuclease and ligating a second short oligonucleotide adapter to the site of IIS restriction endonuclease cleavage; and

(e) selectively amplifying and identifying the sequence differences between the two sample pools to identify a mutation.

10. A method for identifying a genome-wide mutation, comprising:

(a) providing DNA from two sample pools of a subject, wherein a first sample pool is obtained from an diseased cell and a second sample pool is obtained from a normal cell;

(b) digesting each DNA sample pool with Cell to generate at least two DNA fragments;

(c) ligating a short oligonucleotide adapter to each fragment at a site of mismatch cleavage; and

(d) selectively amplifying and identifying the sequence differences between the two sample pools to identify a mutation.